Jacques Courseault, M.D., CAQSM, Author at Physical Medicine and Rehabilitation Qbank Review

About Jacques Courseault, M.D., CAQSM

Dr. Courseault is the CEO/Co-Founder of Medical Board Review, LLC. He is a W. Kennon McWilliams Professor of Sports Medicine at Tulane University, Medical Director of the Tulane Inpatient Rehabilitation Unit, and practices sports medicine and electromyography at the Tulane Institute of Sports Medicine. He has a passion for educating medical students and residents in the "art of physiatry."

Burning Foot – A Complex Cause?

Burning Foot - A Complex Cause? PM&R Case • October, 2017 A 17-year-old female presents to your clinic, referred to you for a burning foot. She is the star high school soccer player and recently fractured her distal tibia and required ORIF. She progressed well in 6 weeks of physical therapy and did not have any issues with recovery. At her last visit, she reported to the therapist that her left foot started to have tingling sensations in it. The therapist recommend that she start to use her crutches again until she can see her orthopedic surgeon, which took two weeks. She [...]

Burning Foot – A Complex Cause?Jacques Courseault, M.D., CAQSM2017-10-24T02:05:52+00:00

PM&R Rounds: EMG and Nerve Injury Prognosis

EMG Predicts Clinical Outcomes PM&R ROUNDS • August 28, 2017 We believe that every PM&R doc should take a look at this article titled How Electrodiagnosis Predicts Clinical Outcome of Focal Peripheral Nerve Lesions, because it further elucidates the importance of EDX consultants in providing a prognosis for nerve lesions. For those who are in practice, CME credit is available through the AANEM. Why We Love This Article Reviews the classification tools used to determine severity of nerve injury. The authors do an excellent job in reviewing the Seddon and Sunderland classifications of nerve injury. They further relate the classifications to prognosis; from [...]

PM&R Rounds: EMG and Nerve Injury PrognosisJacques Courseault, M.D., CAQSM2017-08-28T01:46:22+00:00

Efficacy of Particulate vs Non-Particulate Steroids in Patients with Radicular Pain

Efficacy of Particulate vs Non-Particulate Steroids in Patients with Radicular Pain PM&R News • July 6, 2017 It has been well documented in the literature that particulate steroids carry a significant risk in their use during epidural injections. In fact, there have been 13 reported cases of spinal cord ischemia or posterior circulation infarction after cervical epidural steroid injections and 19 cases of spinal cord ischemia in lumbar epidural steroid injections when using particulate steroids. Even though this risk exists, particulate steroids (triamcinolone, methylprednisolone, betamethasone) are still used by some providers due to theories of better efficacy. This systemic review argues that no [...]

Efficacy of Particulate vs Non-Particulate Steroids in Patients with Radicular PainJacques Courseault, M.D., CAQSM2017-07-06T23:25:58+00:00

Chondroitin vs. Celebrex: Keep NSAIDs on the Shelf?

Chondroitin vs. Celebrex: Keep NSAIDs on the Shelf? PM&R News • June 29, 2017 For many years there has been serious debate whether or not glucosamine, glucosamine and chondroitin or chondroitin alone should be recommended for pain reduction secondary to osteoarthritis. For physiatrists, good benefit with these supplements can lead a pull back on the prescription of potentially detrimental NSAID and/or acetaminophen use. A recent study in the Annals of Rheumatic Diseases sheds further light on the topic. In this study, Reginster et al. recruited 604 patients with symptomatic knee osteoarthritis according to the American College of Rheumatology criteria. Participants were then [...]

Chondroitin vs. Celebrex: Keep NSAIDs on the Shelf?Jacques Courseault, M.D., CAQSM2017-06-30T12:38:08+00:00

Edaravone (Radicava) – ALS Golden Pill?

Radicava - ALS Golden Pill? PM&R News • June 9, 2017 By now you likely have heard that there is a new FDA approved ALS drug named Edaravone (Radicava) on the market. If you haven’t seen the headlines, let's catch you up on the latest buzz. In 2014, a Japanese double blind placebo controlled study evaluated the efficacy and safety of Radicava. One hundred and four patients received the placebo treatment and 102 received Radicava. After 24 weeks of treatment patients’ ALS functional rating scale score decreased by 6.35 points in the placebo but only 5.70 points in the treatment group. Sounds like [...]

Edaravone (Radicava) – ALS Golden Pill?Jacques Courseault, M.D., CAQSM2019-02-26T13:50:05+00:00